<DOC>
	<DOCNO>NCT00313625</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , melphalan busulfan , donor peripheral blood stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving tacrolimus methotrexate transplant may stop happen . PURPOSE : This phase II trial study well give melphalan together busulfan follow donor peripheral stem cell transplant , tacrolimus , methotrexate work treat patient multiple myeloma .</brief_summary>
	<brief_title>Melphalan Busulfan Followed By Donor Peripheral Stem Cell Transplant , Tacrolimus , Methotrexate Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate transplant-related mortality patient multiple myeloma treat myeloablative conditioning regimen comprise melphalan busulfan follow HLA-matched , allogeneic peripheral blood stem cell transplantation ( PBSCT ) graft-vs-host disease prophylaxis tacrolimus methotrexate . Secondary - Determine disease response patient treat regimen . - Determine 1-year progression-free survival overall survival patient treat regimen . OUTLINE : - Conditioning regimen : Patients receive melphalan IV 30 minute day -6 busulfan IV 3 hour day -5 -3 . - Peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo HLA-matched , related donor , allogeneic PBSCT day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive tacrolimus IV continuously orally twice daily begin day -2 continue day 80 follow taper day 180 absence GVHD disease progression . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Stage I disease disease progression second ≥ 2 line prior therapy Stage II III disease , meet 1 follow criterion : Failed achieve least partial response ≥ 2 course prior therapy Progressive disease ≥ 2 course prior therapy Presented highrisk feature diagnosis , include follow : Cytogenetic abnormality Del 13 4,14 fluorescent situ hybridization ( FISH ) Elevated lactic dehydrogenase Beta 2 microglobulin &gt; 5.5 Circulating peripheral blood plasma cell Any stage disease disease progression &gt; 6 month prior autologous stem cell transplantation Availability HLAmatched , relate donor 12 75 year age* No bone marrow donor NOTE : *Donors &gt; 75 year age eligible discretion principal investigator PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Creatinine clearance &gt; 60 mL/min Bilirubin ≤ 2.5 mg/dL ALT/AST &lt; 2 time upper limit normal Cardiac ejection fraction ≥ 49 % DLCO ≥ 50 % correct FEV_1 ≥ 60 % Not pregnant nursing Fertile patient must use effective contraception HIV negative No cirrhosis No chronic inflammatory fibrotic liver disease PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 6 month since prior autologous transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>